Icotrokinra

Icotrokinra
Identifiers
CAS Number	2763602-16-8; hydrochloride: 2763602-17-9;
3D model (JSmol)	Interactive image;
KEGG	D13108;
PubChem CID	162462321;
UNII	MUW8FP7HNZ; hydrochloride: UN7M3WWC8P;
CompTox Dashboard (EPA)	{{#property:P3117}};
	InChI InChI=1S/C90H120N20O22S2/c1-48-16-14-20-59-57(46-97-72(48)59)42-64-79(122)99-60(21-12-13-34-96-50(3)112)77(120)108-75(89(7,8)134-133-88(5,6)74(98-51(4)113)84(127)104-66(44-69(93)115)81(124)107-73(49(2)111)83(126)102-64)85(128)103-62(39-52-23-26-58(27-24-52)132-37-32-91)78(121)100-63(40-53-22-25-55-18-10-11-19-56(55)38-53)82(125)109-90(30-35-131-36-31-90)87(130)106-61(28-29-71(117)118)76(119)101-65(43-68(92)114)80(123)105-67(41-54-17-15-33-95-45-54)86(129)110(9)47-70(94)116/h10-11,14-20,22-27,33,38,45-46,49,60-67,73-75,97,111H,12-13,21,28-32,34-37,39-44,47,91H2,1-9H3,(H2,92,114)(H2,93,115)(H2,94,116)(H,96,112)(H,98,113)(H,99,122)(H,100,121)(H,101,119)(H,102,126)(H,103,128)(H,104,127)(H,105,123)(H,106,130)(H,107,124)(H,108,120)(H,109,125)(H,117,118)/t49-,60+,61+,62+,63+,64+,65+,66+,67+,73+,74-,75-/m1/s1 Key: IVFNYXYPMJQSGF-QMRCQSNESA-N; hydrochloride: Key: CRRBEZHEBBHPMQ-OFJNNPTNSA-N;
	SMILES CC1=C2C(=CC=C1)C(=CN2)C[C@H]3C(=O)N[C@H](C(=O)N[C@@H](C(SSC([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)[C@@H](C)O)CC(=O)N)NC(=O)C)(C)C)(C)C)C(=O)N[C@@H](CC4=CC=C(C=C4)OCCN)C(=O)N[C@@H](CC5=CC6=CC=CC=C6C=C5)C(=O)NC7(CCOCC7)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC8=CN=CC=C8)C(=O)N(C)CC(=O)N)CCCCNC(=O)C;
Properties
Chemical formula	C90H120N20O22S2
Molar mass	1898.19 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Created

2025-04-18 04:48

Contributors

WikiTeq Adm and Dermwiki

Article status

Unassigned

Clinical

Features

Variants

Images

Differential

Histology

Features

Variants

Images

Differential

Pathophysiology

Epidemiology

Associations

Workup

Labs

Imaging

Diagnostic criteria

Management

Treatment

Monitoring

Counseling

Other considerations

Template:Chembox ECHA Template:Chembox E number

Icotrokinra is an investigational targeted oral peptide used in the treatment of plaque psoriasis.^[1]

Description

Icotrokinra is designed to selectively block the IL-23 receptor, which plays a vital role in the pathogenic T-cell activation of plaque psoriasis.^[2]^[3]

The phase 3 ICONIC-LEAD trial has been evaluating icotrokinra in adult and adolescent patients aged 12 years and older with moderate-to-severe cases of plaque psoriasis.^[2]^[4]

The Phase 3 ICONIC-TOTAL study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.^[2]^[5]

Phase 3 studies ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 will evaluate the safety and efficacy of icotrokinra compared with both placebo and deucravacitinib in moderate-to-severe plaque psoriasis.^[6]^[7]

Icotrokinra was jointly discovered by Johnson & Johnson (J&J) and Protagonist Therapeutics.^[2]

References

↑ "J&J pill clears skin in two late-stage psoriasis studies". BioPharma Dive. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
↑ ^2.0 ^2.1 ^2.2 ^2.3 "Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results". JNJ.com. 2024-11-18. Archived from the original on 2024-11-23. Retrieved 2024-11-25.
↑ "Positive Phase 3 Results Announced for JNJ-2113 Treatment of Psoriasis". HCP Live. 2024-11-19. Retrieved 2024-11-25.
↑ "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
↑ "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (ICONIC-TOTAL)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
↑ "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". clinicaltrials.gov. Archived from the original on 2024-07-19. Retrieved 2024-11-25.
↑ "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)". clinicaltrials.gov. Archived from the original on 2024-11-18. Retrieved 2024-11-25.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "J&J pill clears skin in two late-stage psoriasis studies". BioPharma Dive. Archived from the original on 2024-11-19. Retrieved 2024-11-25.

[:0-2] 2.0 ^2.1 ^2.2 ^2.3 "Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results". JNJ.com. 2024-11-18. Archived from the original on 2024-11-23. Retrieved 2024-11-25.

[3] "Positive Phase 3 Results Announced for JNJ-2113 Treatment of Psoriasis". HCP Live. 2024-11-19. Retrieved 2024-11-25.

[4] "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.

[5] "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (ICONIC-TOTAL)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.

[6] "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". clinicaltrials.gov. Archived from the original on 2024-07-19. Retrieved 2024-11-25.

[7] "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)". clinicaltrials.gov. Archived from the original on 2024-11-18. Retrieved 2024-11-25.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Identifiers

CAS Number	2763602-16-8 hydrochloride: 2763602-17-9
3D model (JSmol)	Interactive image
KEGG	D13108
PubChem CID	162462321
UNII	MUW8FP7HNZ hydrochloride: UN7M3WWC8P
CompTox Dashboard (EPA)	{{#property:P3117}}
InChI InChI=1S/C90H120N20O22S2/c1-48-16-14-20-59-57(46-97-72(48)59)42-64-79(122)99-60(21-12-13-34-96-50(3)112)77(120)108-75(89(7,8)134-133-88(5,6)74(98-51(4)113)84(127)104-66(44-69(93)115)81(124)107-73(49(2)111)83(126)102-64)85(128)103-62(39-52-23-26-58(27-24-52)132-37-32-91)78(121)100-63(40-53-22-25-55-18-10-11-19-56(55)38-53)82(125)109-90(30-35-131-36-31-90)87(130)106-61(28-29-71(117)118)76(119)101-65(43-68(92)114)80(123)105-67(41-54-17-15-33-95-45-54)86(129)110(9)47-70(94)116/h10-11,14-20,22-27,33,38,45-46,49,60-67,73-75,97,111H,12-13,21,28-32,34-37,39-44,47,91H2,1-9H3,(H2,92,114)(H2,93,115)(H2,94,116)(H,96,112)(H,98,113)(H,99,122)(H,100,121)(H,101,119)(H,102,126)(H,103,128)(H,104,127)(H,105,123)(H,106,130)(H,107,124)(H,108,120)(H,109,125)(H,117,118)/t49-,60+,61+,62+,63+,64+,65+,66+,67+,73+,74-,75-/m1/s1 Key: IVFNYXYPMJQSGF-QMRCQSNESA-N hydrochloride: Key: CRRBEZHEBBHPMQ-OFJNNPTNSA-N
SMILES CC1=C2C(=CC=C1)C(=CN2)C[C@H]3C(=O)N[C@H](C(=O)N[C@@H](C(SSC([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)[C@@H](C)O)CC(=O)N)NC(=O)C)(C)C)(C)C)C(=O)N[C@@H](CC4=CC=C(C=C4)OCCN)C(=O)N[C@@H](CC5=CC6=CC=CC=C6C=C5)C(=O)NC7(CCOCC7)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC8=CN=CC=C8)C(=O)N(C)CC(=O)N)CCCCNC(=O)C
Properties
Chemical formula	C₉₀H₁₂₀N₂₀O₂₂S₂
Molar mass	1898.19 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references